ADAP

Adaptimmune Therapeutics plc ADR (ADAP) | Rumor.io

Adaptimmune Therapeutics

ADAP

Attention (50-day avg)0%

Attention rank (50-day avg)#4,821

Bullish sentiment (50-day avg)0%

Price to earnings ratio-0.08

Market capitalization5.8M

Earnings per share-0.66

Dividend yield (TTM)—

Revenue (annual)178M

Net income (annual)-70.8M

Social

What share of all stock conversation is about ADAP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% new	0% 0

Oct 28

Adaptimmune Therapeutics (ADAP) has moved to OTC, with its stock price decreasing by over 45%.
The company is developing T-cell therapies for cancer, with its TRuC technology being a key focus area.
Clinical trials and stock performance will be crucial in determining the company's potential upside in 2025.

Generated by AI

Sentiment

Of the messages about ADAP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	44.38% -25.35
Bearish	—	—	—	55.63% +25.35

Bullish· Aug 28

$ADAP is expected to break out above $0.07, potentially leading to a run towards $0.50.
The stock has a strong bid at $0.0675, and breaking above $0.07 could lead to new highs of $0.095-$0.11.
$ADAP and $RAYA are expected to experience significant growth, with $ADAP potentially following in the footsteps of $RAYA and increasing by 100%.

Bearish· May 29

$ADAP has been experiencing significant volatility, with a gap below its current price level, indicating potential downward momentum.
The company's recent performance has been disappointing, with modest numbers and an early-stage development process, according to Mizuho's analysis.
$ADAP's current overbought condition, as indicated by its RSI being over 70, suggests that it may be due for a correction and may experience significant pain ahead.

Generated by AI

Topics

Of the messages about ADAP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	3.2%
Analysts	—	—	0%	22.2%
Controversies	—	—	0%	0.05%
Earnings	—	—	0%	0.02%
Macro	—	—	0%	33.84%
Technical Analysis	—	—	0%	40.69%

Earnings· Mar 15

Adaptimmune Therapeutics plc ($ADAP) reported Q4 EPS loss of $0.05, missing expectations.
$ADAP reported FQ2 earnings of -5c EPS and $4.27M in revenues.
$ADAP beat EPS consensus by 19c, but missed revenue consensus by $5.05M.

Announcements· Jul 28

Adaptimmune Therapeutics plc (ADAP) will sell its cell therapy assets, including TECELRA, lete-cel, afami-cel, and uza-cel, to US WorldMeds for $55M upfront and up to $30M in milestones.
The deal will provide Adaptimmune with an immediate cash injection of $55 million and will allow the company to focus on its preclinical programs, including PRAME and CD70 T-cell therapy.
The sale of the cell therapy assets will also enable Adaptimmune to reduce its burn rate and extend its cash runway until at least October 2025, assuming a quarterly burn rate of $15 million.

Technical Analysis· May 29

$ADAP is experiencing a flag formation, with potential support at 7.40 and resistance at 12.00.
The stock has been churning at a high level, with a notable gap below it, and is being watched for a potential breakout.
Technical indicators suggest $ADAP is overbought, with RSI above 70, potentially indicating a reversal in the near future.

Generated by AI

Community

Of the messages about ADAP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	5.01%
Newcomers	—	—	0%	94.99%

Regulars· Oct 22

The current cash assets of Adaptimmune Therapeutics are around $55M, while the market cap is near $16M, indicating a significant gap between company value and market price, suggesting strong upside potential for $ADAP stock.
The company has retained only pre-clinical programs after the deal and has restructured amid cash-burn concerns and solvency risk, with Mizuho downgrading the stock citing solvency and pipeline risk.
Adaptimmune Therapeutics' stock surged 47.74% to $0.072 in morning trading on elevated volume, with a significant increase in shares changing hands, indicating a potential buying opportunity for investors.

Newcomers· Oct 22

Adaptimmune Therapeutics plc ($ADAP) has announced a voluntary delisting from the Nasdaq and will move to the OTC market, sparking interest from traders and investors.
The company has sold its core cell-therapy portfolio for $55 million, marking a major strategic shift and raising questions about its future direction and potential for growth.
Despite delisting headlines, $ADAP has seen a significant increase in volume, with some traders jumping in on the volatility as the biotech company repositions for survival and potential future success.

Generated by AI

Also Discussed

Investors talking about ADAP also mention

#	Name	Attention
1	4D Molecular Therapeutics, Inc.FDMT	0%new
2	Galapagos NV American Depositary ReceiptGLPG	0%0
3	AFMD - Affimed N.V.	——
4	AtlasClear Holdings, Inc.ATCH	0.01%0
5	ALPN - Alpine Immune Sciences, Inc.	——
6	Palvella Therapeutics IncPIRS	0%0
7	BLCM - Bellicum Pharmaceuticals, Inc.	——
8	Fate Therapeutics Inc.FATE	0%new
9	Cellectis S.A. ADRCLLS	0%new
10	Immunocore Holdings plc ADRIMCR	0%0

Adaptimmune Therapeutics plc ADR

Healthcare
Biotechnology

Adaptimmune Therapeutics plc is a biopharmaceutical company specializing in innovative cell therapies for cancer treatment. The company develops engineered T cell therapies that harness patients' own immune cells to target and destroy cancer cells, utilizing advanced T cell receptor technology to strengthen natural immune responses. Adaptimmune's therapeutic approach focuses on solid tumors and hematological malignancies, including conditions such as synovial sarcoma, multiple myeloma, melanoma, ovarian cancer, and esophageal cancer. The company has achieved significant regulatory milestones, including FDA accelerated approval for its lead therapy and breakthrough therapy designations for additional candidates. Operating as a commercial-stage biopharmaceutical company with operations in the United States and headquarters in Philadelphia and Milton Park, Adaptimmune represents a frontier in cancer immunotherapy by enabling personalized cellular treatments designed to combat some of the most challenging malignancies.

Website

Location

The Innovation Centre

Abingdon, OX14 4RY

United Kingdom

Social

What share of all stock conversation is about ADAP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% new	0% 0

Oct 28

Adaptimmune Therapeutics (ADAP) has moved to OTC, with its stock price decreasing by over 45%.
The company is developing T-cell therapies for cancer, with its TRuC technology being a key focus area.
Clinical trials and stock performance will be crucial in determining the company's potential upside in 2025.

Generated by AI

Sentiment

Of the messages about ADAP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	44.38% -25.35
Bearish	—	—	—	55.63% +25.35

Bullish· Aug 28

$ADAP is expected to break out above $0.07, potentially leading to a run towards $0.50.
The stock has a strong bid at $0.0675, and breaking above $0.07 could lead to new highs of $0.095-$0.11.
$ADAP and $RAYA are expected to experience significant growth, with $ADAP potentially following in the footsteps of $RAYA and increasing by 100%.

Bearish· May 29

$ADAP has been experiencing significant volatility, with a gap below its current price level, indicating potential downward momentum.
The company's recent performance has been disappointing, with modest numbers and an early-stage development process, according to Mizuho's analysis.
$ADAP's current overbought condition, as indicated by its RSI being over 70, suggests that it may be due for a correction and may experience significant pain ahead.

Generated by AI

Topics

Of the messages about ADAP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	3.2%
Analysts	—	—	0%	22.2%
Controversies	—	—	0%	0.05%
Earnings	—	—	0%	0.02%
Macro	—	—	0%	33.84%
Technical Analysis	—	—	0%	40.69%

Earnings· Mar 15

Adaptimmune Therapeutics plc ($ADAP) reported Q4 EPS loss of $0.05, missing expectations.
$ADAP reported FQ2 earnings of -5c EPS and $4.27M in revenues.
$ADAP beat EPS consensus by 19c, but missed revenue consensus by $5.05M.

Announcements· Jul 28

Adaptimmune Therapeutics plc (ADAP) will sell its cell therapy assets, including TECELRA, lete-cel, afami-cel, and uza-cel, to US WorldMeds for $55M upfront and up to $30M in milestones.
The deal will provide Adaptimmune with an immediate cash injection of $55 million and will allow the company to focus on its preclinical programs, including PRAME and CD70 T-cell therapy.
The sale of the cell therapy assets will also enable Adaptimmune to reduce its burn rate and extend its cash runway until at least October 2025, assuming a quarterly burn rate of $15 million.

Technical Analysis· May 29

$ADAP is experiencing a flag formation, with potential support at 7.40 and resistance at 12.00.
The stock has been churning at a high level, with a notable gap below it, and is being watched for a potential breakout.
Technical indicators suggest $ADAP is overbought, with RSI above 70, potentially indicating a reversal in the near future.

Generated by AI

Community

Of the messages about ADAP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	5.01%
Newcomers	—	—	0%	94.99%

Regulars· Oct 22

The current cash assets of Adaptimmune Therapeutics are around $55M, while the market cap is near $16M, indicating a significant gap between company value and market price, suggesting strong upside potential for $ADAP stock.
The company has retained only pre-clinical programs after the deal and has restructured amid cash-burn concerns and solvency risk, with Mizuho downgrading the stock citing solvency and pipeline risk.
Adaptimmune Therapeutics' stock surged 47.74% to $0.072 in morning trading on elevated volume, with a significant increase in shares changing hands, indicating a potential buying opportunity for investors.

Newcomers· Oct 22

Adaptimmune Therapeutics plc ($ADAP) has announced a voluntary delisting from the Nasdaq and will move to the OTC market, sparking interest from traders and investors.
The company has sold its core cell-therapy portfolio for $55 million, marking a major strategic shift and raising questions about its future direction and potential for growth.
Despite delisting headlines, $ADAP has seen a significant increase in volume, with some traders jumping in on the volatility as the biotech company repositions for survival and potential future success.

Generated by AI

Adaptimmune Therapeutics

Social

Oct 28

Sentiment

Bullish· Aug 28

Bearish· May 29

Topics

Earnings· Mar 15

Announcements· Jul 28

Technical Analysis· May 29

Community

Regulars· Oct 22

Newcomers· Oct 22

Also Discussed

Adaptimmune Therapeutics plc ADR

Company Information

Location

Also Discussed

Social

Oct 28

Sentiment

Bullish· Aug 28

Bearish· May 29

Topics

Earnings· Mar 15

Announcements· Jul 28

Technical Analysis· May 29

Community

Regulars· Oct 22

Newcomers· Oct 22